Kinetics of hiv-1 in cerebrospinal fluid and serum after zidovudine treatment

Journal of Neuro-AIDS

Volumn 2, Issue 2, 1999, Pages 29-35

  Hagberg, Lars ^a   Gisslen, Magnus ^a   Norkrans, Gunnar ^a   Svennerholm, Bo ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; HIV; Serum; Zidovudin

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; VIRUS DETECTION; VIRUS ENCEPHALITIS; VIRUS LOAD;

EID: 0033461204     PISSN: 10697438     EISSN: None     Source Type: Journal    
DOI: 10.1300/J128v02n02_03     Document Type: Article

References (14)

1. Fischl MA, Richman DD, Grieco MH et al., and the AZT collaborative working group. The efficacy of azidothymidine (AZT) in the treatment of participants with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-191.
2. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343:871-878.
3. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on cerebrospinal fluid HIV RNA levels after initiation of zidovudine or didanosine. J Infect Dis 1997; 175:434-437
4. Katzenstein DA, Hammer SM, Hughes MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleotide therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimetre. N Engl J Med 1996; 335: 1091-1098.
5. O’Brien WA, Hartigan PM, Martin D et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334:426-431.
6. Klecker RW, Collins JM, Yarchoan R et al. Plasma and cerebrospinal fluid pharmakokinetics of 3'a-2,3'-deoxythymidine: a novel pyrimidin analogue with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41:407-412.
7. Hagberg L, Andersson M, Chiodi F et al. Effect of zidovudine on cerebrospinal fluid in patients with HIV infection and acute neurological disease. Scand J Infect Dis 1991; 23:681-685.
8. Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J of Clin Microbiology 1995; 33(2):352-355.
9. Lafeuillade A, Poggi C, Pellegrino P, Corti K, Profizi N, Sayada C. HIV-1 replication in the plasma and cerebrospinal fluid. Infection 1996; 24:367-371.
10. Portegies P, Enting RH, de Gans J et al. Presentation and course of AIDS dementia complex: 10 years follow up in Amsterdam, The Netherlands. AIDS 1993; 7:669-675.
11. Chiesi A, Vella S, Dally LG et al. Epidemiology of AIDS dementia complex in Europe. Journal of Acquried Immune Deficiency Syndromes and Human Retro-virology 1996; 11:39-44.
12. Gisslen M, Chiodi F, Fuchs D et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: A longitudinal study. Scand J Infect Dis 1994; 26:523-533.
13. Gisslen M, Hagberg L, Svennerholm B, Norkrans G. HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997; 11:1194.
14. Elovaara I, Seppala I, Poutiainen E, Suni J, Valle SL. Intrathecal humoral immunologic response in neurologically symptomatic and asymptomatic patients with human immunodeficiency virus infection. Neurology 1988; 38(9):1451-1456.